- BC Partners has agreed to acquire a co-control stake in InfoRLife from its Founder and CEO Sergio Dusci and the founding families of ACS Dobfar. Financial terms of the transaction were not disclosed.
- The investment will support InfoRLife’s growth through increased R&D investment, product pipeline expansion, operational improvements, and mergers and acquisitions.
BC Partners has agreed to acquire a co-control stake in InfoRLife SA from Founder and Chief Executive Officer Sergio Dusci and the founding families of ACS Dobfar. Financial terms of the transaction were not disclosed. The investment firm said it will partner with ACS to support the next phase of growth for the Switzerland-based CDMO.
Founded in 2002 as a division of ACS, InfoRLife is a business-to-business dossier developer and contract manufacturing organization focused on the ready-to-use (RTU) IV infusion bag market. The company provides end-to-end development, manufacturing, and out-licensing services and operates facilities in Switzerland, Romania, and Tunisia. According to the company, demand for RTU IV infusion bags is increasing as hospitals seek safer, more efficient, and cost-effective drug delivery solutions.
Under the agreement, BC Partners plans to invest in research and development, broaden InfoRLife’s product pipeline, improve operational performance, and pursue mergers and acquisitions. “Our investment in InfoRLife builds on BC Partners’ strong track record in the generics space,” said Matt Evans, Partner at BC Partners.
BC Partners said the investment represents the second acquisition for BC Partners Fund XII, following its acquisition of Fortidia. The fund will continue its sector-focused investment strategy, targeting a diversified portfolio of defensive growth companies in the mid-market.
BC Partners was advised by Latham & Watkins, Studio Legale Tributario Facchini Rossi Michelutti, PwC, Bär & Karrer, Jefferies, and Rothschild. ACS was advised by Alira Health and LCA.
